← Latest Braidwell portfolio

Braidwell portfolio · 2023-03-31

Form 13F reports holdings as of 2023-03-31 and was filed on 2023-05-15. It is delayed, can omit confidential positions, and is not the manager's current portfolio or fund NAV. Options show reported underlying value—not premium, net exposure, or investment intent.

Disclosed long book

$1.62 billion

Long positions

81

Calls / puts

0 / 0

Top 5 concentration

24.9%

Longs with AI data

0 / 81

Average AI 1Y

PositionKindSharesValueLong weightQuarter changeAI at filing · 1YAI now

GUARDANT HEALTH INC

GUARDANT HEALTH INC · NOTE 11/1 · 40131MAB5

LONG 250,022,000 $168.8 million NEWLY REPORTED

1Y —

5Y —

EXACT SCIENCES CORP

EXACT SCIENCES CORP · NOTE 0.375% 3/0 · 30063PAC9

LONG 139,000,000 $122.7 million NEWLY REPORTED

1Y —

5Y —

NANOSTRING TECHNOLOGIES INC

NANOSTRING TECHNOLOGIES INC · NOTE 2.625% 3/0 · 63009RAD1

LONG 145,520,000 $121.8 million NEWLY REPORTED

1Y —

5Y —

NOVOCURE LTD

NOVOCURE LTD · NOTE 11/0 · 67011XAB9

LONG 134,334,000 $116.8 million NEWLY REPORTED

1Y —

5Y —

ALPHATEC HLDGS INC

ALPHATEC HLDGS INC · NOTE 0.750% 8/0 · 02081GAB8

LONG 101,250,000 $108.2 million NEWLY REPORTED

1Y —

5Y —

BRIDGEBIO PHARMA INC

BRIDGEBIO PHARMA INC · NOTE 2.500% 3/1 · 10806XAB8

LONG 143,338,000 $106.2 million NEWLY REPORTED

1Y —

5Y —

NEVRO CORP

NEVRO CORP · NOTE 2.750% 4/0 · 64157FAC7

LONG 109,251,000 $102.7 million NEWLY REPORTED

1Y —

5Y —

GLAUKOS CORP

GLAUKOS CORP · COM · 377322102

LONG 1,806,651 $90.5 million 5.6% INCREASED

1Y —

5Y —

IVERIC BIO INC

IVERIC BIO INC · COM · 46583P102

LONG 3,714,672 $90.4 million 5.6% INCREASED

1Y —

5Y —

NEUROCRINE BIOSCIENCES INC

NEUROCRINE BIOSCIENCES INC · COM · 64125C109

LONG 766,800 $77.6 million 4.8% NEWLY REPORTED

1Y —

5Y —

XENON PHARMACEUTICALS INC

XENON PHARMACEUTICALS INC · COM · 98420N105

LONG 2,137,110 $76.5 million 4.7% INCREASED

1Y —

5Y —

ALIGN TECHNOLOGY INC

ALIGN TECHNOLOGY INC · COM · 016255101

LONG 207,130 $69.2 million 4.3% REDUCED

1Y —

5Y —

BIOGEN INC

BIOGEN INC · COM · 09062X103

LONG 220,742 $61.4 million 3.8% REDUCED

1Y —

5Y —

NEVRO CORP

NEVRO CORP · COM · 64157F103

LONG 1,632,915 $59.0 million 3.6% INCREASED

1Y —

5Y —

INTUITIVE SURGICAL INC

INTUITIVE SURGICAL INC · COM NEW · 46120E602

LONG 223,120 $57.0 million 3.5% UNCHANGED

1Y —

5Y —

IRHYTHM HOLDINGS INC

IRHYTHM HOLDINGS INC · COM · 450056106

LONG 454,169 $56.3 million 3.5% REDUCED

1Y —

5Y —

NATERA INC

NATERA INC · COM · 632307104

LONG 982,241 $54.5 million 3.4% REDUCED

1Y —

5Y —

TRAVERE THERAPEUTICS INC

TRAVERE THERAPEUTICS INC · NOTE 2.500% 9/1 · 761299AB2

LONG 56,031,000 $53.9 million NEWLY REPORTED

1Y —

5Y —

NUVASIVE INC

NUVASIVE INC · NOTE 1.000% 6/0 · 670704AL9

LONG 51,500,000 $51.1 million NEWLY REPORTED

1Y —

5Y —

KARYOPHARM THERAPEUTICS INC

KARYOPHARM THERAPEUTICS INC · NOTE 3.000%10/1 · 48576UAA4

LONG 65,976,000 $51.1 million NEWLY REPORTED

1Y —

5Y —

DECIPHERA PHARMACEUTICALS IN

DECIPHERA PHARMACEUTICALS IN · COM · 24344T101

LONG 3,241,351 $50.1 million 3.1% REDUCED

1Y —

5Y —

VAXCYTE INC

VAXCYTE INC · COM · 92243G108

LONG 1,319,978 $49.5 million 3.0% REDUCED

1Y —

5Y —

IONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS INC · NOTE 4/0 · 462222AD2

LONG 52,740,000 $48.1 million NEWLY REPORTED

1Y —

5Y —

EXACT SCIENCES CORP

EXACT SCIENCES CORP · NOTE 0.375% 3/1 · 30063PAB1

LONG 48,300,000 $45.2 million NEWLY REPORTED

1Y —

5Y —

ORTHOPEDIATRICS CORP

ORTHOPEDIATRICS CORP · COM · 68752L100

LONG 998,871 $44.2 million 2.7% REDUCED

1Y —

5Y —

DAY ONE BIOPHARMACEUTICALS I

DAY ONE BIOPHARMACEUTICALS I · COM · 23954D109

LONG 3,159,895 $42.2 million 2.6% INCREASED

1Y —

5Y —

ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC · COM · 29251M106

LONG 1,038,310 $42.0 million 2.6% INCREASED

1Y —

5Y —

AMYRIS INC

AMYRIS INC · NOTE 1.500%11/1 · 03236MAJ0

LONG 137,850,000 $39.1 million NEWLY REPORTED

1Y —

5Y —

AMGEN INC

AMGEN INC · COM · 031162100

LONG 161,500 $39.0 million 2.4% INCREASED

1Y —

5Y —

INSMED INC

INSMED INC · NOTE 1.750% 1/1 · 457669AA7

LONG 39,963,000 $36.5 million NEWLY REPORTED

1Y —

5Y —

NEOGENOMICS INC

NEOGENOMICS INC · NOTE 0.250% 1/1 · 64049MAB6

LONG 48,678,000 $36.0 million NEWLY REPORTED

1Y —

5Y —

IONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS INC · NOTE 0.125%12/1 · 462222AB6

LONG 36,533,000 $33.8 million NEWLY REPORTED

1Y —

5Y —

NUVASIVE INC

NUVASIVE INC · NOTE 0.375% 3/1 · 670704AJ4

LONG 36,665,000 $32.5 million NEWLY REPORTED

1Y —

5Y —

CRINETICS PHARMACEUTICALS IN

CRINETICS PHARMACEUTICALS IN · COM · 22663K107

LONG 2,019,714 $32.4 million 2.0% REDUCED

1Y —

5Y —

OUTSET MED INC

OUTSET MED INC · COM · 690145107

LONG 1,754,350 $32.3 million 2.0% INCREASED

1Y —

5Y —

NEOGENOMICS INC

NEOGENOMICS INC · NOTE 1.250% 5/0 · 64049MAA8

LONG 33,000,000 $31.0 million NEWLY REPORTED

1Y —

5Y —

HARROW INC

HARROW INC · COM · 415858109

LONG 1,452,538 $30.7 million 1.9% NEWLY REPORTED

1Y —

5Y —

PENUMBRA INC

PENUMBRA INC · COM · 70975L107

LONG 107,044 $29.8 million 1.8% REDUCED

1Y —

5Y —

BELLUS HEALTH INC NEW

BELLUS HEALTH INC NEW · COM NEW · 07987C204

LONG 4,126,194 $29.7 million 1.8% INCREASED

1Y —

5Y —

LEGEND BIOTECH CORP

LEGEND BIOTECH CORP · SPONSORED ADS · 52490G102

LONG 601,801 $29.0 million 1.8% REDUCED

1Y —

5Y —

DICE THERAPEUTICS INC

DICE THERAPEUTICS INC · COM · 23345J104

LONG 984,800 $28.2 million 1.7% INCREASED

1Y —

5Y —

TRAVERE THERAPEUTICS INC

TRAVERE THERAPEUTICS INC · NOTE 2.250% 3/0 · 89422GAA5

LONG 28,350,000 $27.9 million NEWLY REPORTED

1Y —

5Y —

KRYSTAL BIOTECH INC

KRYSTAL BIOTECH INC · COM · 501147102

LONG 348,036 $27.9 million 1.7% REDUCED

1Y —

5Y —

BRIDGEBIO PHARMA INC

BRIDGEBIO PHARMA INC · NOTE 2.250% 2/0 · 10806XAD4

LONG 42,294,000 $27.4 million NEWLY REPORTED

1Y —

5Y —

MERUS N V

MERUS N V · COM · N5749R100

LONG 1,473,084 $27.1 million 1.7% REDUCED

1Y —

5Y —

HILLEVAX INC

HILLEVAX INC · COM · 43157M102

LONG 1,620,216 $26.8 million 1.6% UNCHANGED

1Y —

5Y —

ACLARIS THERAPEUTICS INC

ACLARIS THERAPEUTICS INC · COM · 00461U105

LONG 3,269,094 $26.4 million 1.6% INCREASED

1Y —

5Y —

TERNS PHARMACEUTICALS INC

TERNS PHARMACEUTICALS INC · COM · 880881107

LONG 1,997,055 $23.6 million 1.5% NEWLY REPORTED

1Y —

5Y —

ANAPTYSBIO INC

ANAPTYSBIO INC · COM · 032724106

LONG 973,073 $21.2 million 1.3% INCREASED

1Y —

5Y —

IMMUNOCORE HLDGS PLC

IMMUNOCORE HLDGS PLC · ADS · 45258D105

LONG 426,110 $21.1 million NEWLY REPORTED

1Y —

5Y —

DBV TECHNOLOGIES S A

DBV TECHNOLOGIES S A · SPONSORED ADR · 23306J101

LONG 12,107,785 $20.5 million 1.3% UNCHANGED

1Y —

5Y —

ALECTOR INC

ALECTOR INC · COM · 014442107

LONG 3,206,315 $19.8 million 1.2% INCREASED

1Y —

5Y —

SYNDAX PHARMACEUTICALS INC

SYNDAX PHARMACEUTICALS INC · COM · 87164F105

LONG 920,049 $19.4 million 1.2% REDUCED

1Y —

5Y —

GLOBUS MED INC

GLOBUS MED INC · CL A · 379577208

LONG 335,200 $19.0 million 1.2% REDUCED

1Y —

5Y —

PARAGON 28 INC

PARAGON 28 INC · COM · 69913P105

LONG 1,098,722 $18.8 million 1.2% NEWLY REPORTED

1Y —

5Y —

STERIS PLC

STERIS PLC · SHS USD · G8473T100

LONG 95,694 $18.3 million 1.1% UNCHANGED

1Y —

5Y —

MIRATI THERAPEUTICS INC

MIRATI THERAPEUTICS INC · COM · 60468T105

LONG 452,000 $16.8 million 1.0% INCREASED

1Y —

5Y —

BIOCRYST PHARMACEUTICALS INC

BIOCRYST PHARMACEUTICALS INC · COM · 09058V103

LONG 1,945,134 $16.2 million 1.0% NEWLY REPORTED

1Y —

5Y —

DYNE THERAPEUTICS INC

DYNE THERAPEUTICS INC · COM · 26818M108

LONG 1,377,872 $15.9 million 1.0% INCREASED

1Y —

5Y —

INVITAE CORP

INVITAE CORP · NOTE 2.000% 9/0 · 46185LAB9

LONG 16,781,000 $14.8 million NEWLY REPORTED

1Y —

5Y —

VIR BIOTECHNOLOGY INC

VIR BIOTECHNOLOGY INC · COM · 92764N102

LONG 604,036 $14.1 million 0.9% NEWLY REPORTED

1Y —

5Y —

MERSANA THERAPEUTICS INC

MERSANA THERAPEUTICS INC · COM · 59045L106

LONG 3,355,805 $13.8 million 0.8% INCREASED

1Y —

5Y —

PULMONX CORP

PULMONX CORP · COM · 745848101

LONG 1,163,294 $13.0 million 0.8% REDUCED

1Y —

5Y —

PACIFIC BIOSCIENCES CALIF IN

PACIFIC BIOSCIENCES CALIF IN · COM · 69404D108

LONG 1,097,300 $12.7 million 0.8% NEWLY REPORTED

1Y —

5Y —

COMPASS THERAPEUTICS INC

COMPASS THERAPEUTICS INC · COM · 20454B104

LONG 3,247,847 $10.6 million 0.7% INCREASED

1Y —

5Y —

ARCELLX INC

ARCELLX INC · COMMON STOCK · 03940C100

LONG 333,800 $10.3 million 0.6% NEWLY REPORTED

1Y —

5Y —

ARGENX SE

ARGENX SE · SPONSORED ADR · 04016X101

LONG 24,600 $9.2 million 0.6% REDUCED

1Y —

5Y —

AXONICS INC

AXONICS INC · COM · 05465P101

LONG 166,704 $9.1 million 0.6% NEWLY REPORTED

1Y —

5Y —

MINERALYS THERAPEUTICS INC

MINERALYS THERAPEUTICS INC · COM · 603170101

LONG 550,300 $8.6 million 0.5% NEWLY REPORTED

1Y —

5Y —

TRANSMEDICS GROUP INC

TRANSMEDICS GROUP INC · COM · 89377M109

LONG 98,459 $7.5 million 0.5% REDUCED

1Y —

5Y —

NUVATION BIO INC

NUVATION BIO INC · COM CL A · 67080N101

LONG 4,122,900 $6.8 million 0.4% UNCHANGED

1Y —

5Y —

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS · NOTE 0.625% 4/0 · 868459AD0

LONG 6,500,000 $6.5 million NEWLY REPORTED

1Y —

5Y —

ADAPTIVE BIOTECHNOLOGIES COR

ADAPTIVE BIOTECHNOLOGIES COR · COM · 00650F109

LONG 648,451 $5.7 million 0.4% NEWLY REPORTED

1Y —

5Y —

ALX ONCOLOGY HLDGS INC

ALX ONCOLOGY HLDGS INC · COM · 00166B105

LONG 1,249,900 $5.6 million 0.3% INCREASED

1Y —

5Y —

INSMED INC

INSMED INC · NOTE 0.750% 6/0 · 457669AB5

LONG 3,500,000 $2.7 million NEWLY REPORTED

1Y —

5Y —

SILK RD MED INC

SILK RD MED INC · COM · 82710M100

LONG 63,331 $2.5 million 0.2% REDUCED

1Y —

5Y —

IMMATICS N.V

IMMATICS N.V · SHS · N44445109

LONG 322,287 $2.2 million 0.1% REDUCED

1Y —

5Y —

ESPERION THERAPEUTICS INC NE

ESPERION THERAPEUTICS INC NE · COM · 29664W105

LONG 1,211,519 $1.9 million 0.1% REDUCED

1Y —

5Y —

REPLIMUNE GROUP INC

REPLIMUNE GROUP INC · COM · 76029N106

LONG 73,665 $1.3 million 0.1% REDUCED

1Y —

5Y —

ILLUMINA INC

ILLUMINA INC · NOTE 8/1 · 452327AK5

LONG 11,100,000 $1.1 million NEWLY REPORTED

1Y —

5Y —

AVALO THERAPEUTICS INC

AVALO THERAPEUTICS INC · COM NEW · 05338F207

LONG 247,254 $432,695 0.0% NEWLY REPORTED

1Y —

5Y —

AI outlook values are averages across the latest successful run per covered model at the labeled cutoff. “No longer reported” does not necessarily mean sold; thresholds, confidential treatment, corporate actions, or instrument changes may explain an omission. Reviewed API mapping covers 0.0% of disclosed long-book value; exact editorial CUSIP mappings may add current-only AI coverage on this public page. Research use only. No warranty and not investment advice.